Journal of Nanobiotechnology 2021

4 papers
In 2021, the Journal of Nanobiotechnology published research centered on the development and clinical translation of complex nanomedicines. Key research directions included the engineering of carrier-free self-assembling nanoparticles for drug delivery and the use of active surface targeting to improve therapeutic precision. Significant attention was directed toward the long-term biological fate of engineered nanomaterials and the modeling of tumor microenvironments to bridge the translational gap. Other prominent themes involved enhancing the bioavailability of natural products through nanoscale systems and the design of acid-sensitive switches for targeted drug release. Specific studies explored catalytic nanoplatforms, such as ruthenium-loaded mesoporous silica acting as nano-Fenton reactors for cancer therapy. Research also investigated dual-targeting ruthenium nanodrugs designed to inhibit tumor growth and metastasis via the PARP/ATM pathway. Additionally, the journal highlighted molecularly engineered nanoassemblies for photothermal therapy and Her2-specific affibody-mediated systems for chemo-radiotherapy. Prolific contributors to these advancements included researchers such as Di Zhu, Jiawang Liu, and Wenjing Wang, who focused on strategies to induce mitotic catastrophe and inhibit pathological vessel growth in tumors.

Top Research Directions

The 17 research directions with Journal of Nanobiotechnology 2021 papers, ranked by paper count, next to 2020. Share is the fraction of the edition’s papers in the direction.

#Direction20212020Share 2021Share 20202020 rank
1Carrier Free Self Assembly of Active Pharmaceutical Ingredients2050.0%0.0%—
2Catalytic Oxygen Generation to Overcome Tumor Hypoxia2050.0%0.0%—
3Ligand Mediated Active Targeting of Nanocarriers2150.0%33.3%4
4Long-Term Clearance and Bioaccumulation of Therapeutic Nanomaterials2050.0%0.0%—
5Overcoming the Scalability Bottleneck in Nanomedicine Synthesis2050.0%0.0%—
6Achieving Therapeutic Selectivity in Cancer Chemotherapy1025.0%0.0%—
7Bridging the Preclinical Translation Gap in Nanomedicine1025.0%0.0%—
8Integrating Diagnostic Imaging and Targeted Therapy1025.0%0.0%—
9Microenvironment Triggered Cargo Release from Smart Nanocarriers1025.0%0.0%—
10Overcoming Bioavailability Barriers for Poorly Soluble Compounds1025.0%0.0%—
11Overcoming the One Percent Nanoparticle Delivery Bottleneck1025.0%0.0%—
12Overcoming Tumor Hypoxia in Oxygen-Dependent Cancer Therapies1025.0%0.0%—
13Physiological Validation of Reductionist Molecular Mechanisms1025.0%0.0%—
14Starving Tumors Through Angiogenic Factor Downregulation1025.0%0.0%—
15Synergistic Hyperthermic and Chemical Cancer Therapy1125.0%33.3%10
16Targeting Cell Cycle Checkpoints for Cancer Therapy1025.0%0.0%—
17The Preclinical Toxicity Assessment Gap1025.0%0.0%—

Download all directions as CSV

Institutions

Institutions credited by Journal of Nanobiotechnology 2021 papers: a paper credits every institution named in its affiliations, once. 5 institutions share 4 credited papers.

#InstitutionPapersShare20202020 rank
105jb9pq57 250.0%0—
201413r497 125.0%0—
303dnytd23 125.0%0—
4Capital Medical University 125.0%0—
5Donghua University 125.0%0—

Download all institutions as CSV

About this data

Papers. Journal of Nanobiotechnology 2021 lists 4 papers on Lacuna, duplicate versions counted once; rejected and withdrawn submissions are left out.

Directions. Directions are Lacuna’s clustering of the concept elements extracted from each paper, so a paper can belong to several and direction counts add up to more than the paper count. A direction’s share is its papers divided by the edition’s papers. Comparisons with 2020 use shares, since the edition went from 3 to 4 papers.

Institutions. A paper credits each institution named in its affiliations, resolved to a ROR record, once. 4 of 4 papers (100.0%) credit at least one institution and are the base for institution shares; the rest have no resolved affiliation yet.

Data. Counts come from Lacuna’s data build of 2026-11-19 and change as papers are added. Tables as CSV: directions · institutions. Cite as: Lacuna, “Journal of Nanobiotechnology 2021”, https://lacuna.tiptreesystems.com/venue/journal-of-nanobiotechnology/2021.

Impactful Papers

Papers from Journal of Nanobiotechnology 2021 that shaped research clusters.

Influential

Papers

Title
A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway
Dimeric Her2-specific affibody mediated cisplatin-loaded nanoparticles for tumor enhanced chemo-radiotherapy
Molecularly engineered carrier-free co-delivery nanoassembly for self-sensitized photothermal cancer therapy
Ruthenium-loaded mesoporous silica as tumor microenvironment-response nano-fenton reactors for precise cancer therapy